Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04573062 · ClinicalTrials.gov registry record
Natural History of Post-Coronavirus Disease 19 Convalescence at the National Institutes of Health
A clinical trial of Post-Coronavirus Disease 19, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- Recruiting
- Registry status
- 1,590
- Enrollment target
- 1
- Study location
NCT04573062: Recruiting study of Post-Coronavirus Disease 19, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
NCT04573062 is a study of Post-Coronavirus Disease 19 that is actively recruiting participants, run by National Institute of Neurological Disorders and Stroke (NINDS). The registered enrollment target is 1,590 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04573062, a study of Post-Coronavirus Disease 19, is actively recruiting participants, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- RECRUITING
- Registry status
- 1,590 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: People who get COVID-19 have a wide range of symptoms. They also recover from COVID-19 in different ways. In this study, researchers will use survey data to describe the different ways people experience and recover from COVID-19. They will also use the data to help create future studies to understand why some people do not fully recover. Objective: To learn more about the range and timing of symptoms that people have before, during, and after COVID-19 infection. Eligibility: People ages 18 and older who can give documentation of a positive COVID-19 or antibody test. Design: Participants will be screened with a telephone interview. It will take 15 minutes. They will provide their COVID-19 test results and medical records. Participants will complete a second telephone interview. It will take 30 60 minutes. They will also take online surveys every 3 months for 3 years. The interview and surveys will ask participants about their health before they got COVID-19, what happened while they had COVID-19, and what their recovery has been like. Participants will get log-in data to take the online surveys. Completing all of the surveys the first time may take up to 3 hours. Follow-up surveys will take up to 30 minutes. Participants do not have to complete the surveys in one sitting. They will be able to save their progress and finish the surveys later. Participants may be contacted to take part in other research studies.
Primary Outcome
The number and severity of persistent symptoms associated with COVID-19 convalescence. Collected data will be used to characterize different narratives of COVID-19 convalescence.
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,590 participants |
| Start Date | 2022-01-02 |
| Est. Completion | 2027-12-31 |
What NCT04573062 shows while recruiting
NCT04573062 is an observational study that tracks outcomes without assigning an intervention. Its 1,590 participants enrollment target places it among the larger protocols in the corpus.
The record links to 1 condition, with Post-Coronavirus Disease 19 appearing as the primary indexed condition, and to 0 interventions.
NCT04573062 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT04573062 about?
NCT04573062 is a clinical study titled "Natural History of Post-Coronavirus Disease 19 Convalescence at the National Institutes of Health". Background: People who get COVID-19 have a wide range of symptoms. They also recover from COVID-19 in different ways. In this study, researchers will use survey data to describe the different ways people experience and recover from COVID-19. They will also use the data to help create future studies...
What is the current status of trial NCT04573062?
This trial is currently recruiting. The enrollment target is 1,590 participants. The study started on 2022-01-02. Estimated completion is 2027-12-31.
What conditions does trial NCT04573062 study?
This clinical trial studies the following conditions: Post-Coronavirus Disease 19.
Who is sponsoring clinical trial NCT04573062?
This trial is sponsored by National Institute of Neurological Disorders and Stroke (NINDS), which has 567 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04573062 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05552222 · 1,590 participants · Phase 3
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- NCT06632457 · 1,590 participants · Phase 3
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
- NCT05243797 · 1,594 participants · Phase 3
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- NCT00646022 · 1,600 participants
Natural History of Familial Carcinoid Tumor
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI